Evolent Health Receives 'Moderate Buy' Consensus from Analysts

Seventeen research firms cover the healthcare tech company's stock.

Apr. 15, 2026 at 6:43am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of heavy, industrial banking equipment and mechanics, conveying a sense of institutional power and the underlying infrastructure of the financial system.Evolent Health's stock performance reflects the complex financial machinery and institutional forces shaping the healthcare technology industry.Arlington Today

Shares of Evolent Health, Inc. (NYSE:EVH) have received a 'Moderate Buy' consensus rating from the seventeen research firms currently covering the company, according to MarketBeat.com. One analyst has a 'Sell' rating, three have 'Hold' ratings, and thirteen have 'Buy' ratings on the stock, with an average 12-month price target of $6.04.

Why it matters

Evolent Health is a healthcare technology and services company that partners with health systems, physician groups, and health plans to design and operate value-based care programs. The 'Moderate Buy' consensus from analysts suggests they see potential upside in the company's stock despite some recent challenges, as Evolent navigates the industry's shift towards value-based care.

The details

The analysts' ratings and price targets on Evolent Health stock have fluctuated in recent months. KeyCorp downgraded the stock from 'Overweight' to 'Sector Weight' in February, while several other firms cut their price targets, citing factors like the company's Q4 2025 results and the broader market environment.

  • Evolent Health reported Q4 2025 earnings on February 24, 2026.
  • The company's stock hit a 52-week low of $2.10 during the past year.

The players

Evolent Health, Inc.

A healthcare technology and services company that partners with health systems, physician groups, and health plans to design and operate value-based care programs.

KeyCorp

A financial services company that recently downgraded Evolent Health's stock rating.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Evolent Health can execute on its value-based care strategy and whether the company's stock price can rebound from its recent lows.

The takeaway

Evolent Health's 'Moderate Buy' consensus rating suggests analysts see potential in the company's healthcare technology and services offerings, even as it navigates a challenging market environment and transitions towards value-based care models.